The California-based Arrayit Corporation has quickly evolved into a leader in life sciences and the overall healthcare field. Arrayit Corporations subsidiary Arrayit Diagnostics has gained recognition for detecting cancer in early stages which has made them a friend to both investors and cancer patients. Today, Arrayit Corporation took a major step towards enhancing their future with the announcement that they have joined forces with DOCRO, Inc.
DOCRO is a renowned contract research organization which specializes in the design and conduct of clinical trials of in vitro diagnostic clearance from the U.S. Food and Drug Administration (FDA). DOCRO has steered close to 100 In Vitro Diagnostic (IVD) clinical trials through the FDA in the past 12 years and has an incredible 99% success rate with the organization. DOCRO has been sought by Arrayit to expedite submission and approval of the company’s Pre-Symptomatic Ovarian Cancer Screening Test, the OvaDx.
Arrayit’s OvaDx will be the first comprehensive diagnostic screen for Ovarian Cancer and will be recommended for all women over the age of 35. With the state-of-the-art technology utilized by Arrayit, the OvaDx will detect both early and late stage Ovarian Cancer and provide patients a much greater chance of survival and a higher quality of life.
When asked what the addition of DOCRO will mean to OvaDx and the Arrayit Corporation as a whole, Rene Schena who serves as the company’s CEO was quoted as saying, “We are pleased to retain DOCRO for FDA approval of OvaDx. DOCRO brings a breadth and depth of experience that matches the importance of bringing the first early stage pre-symptomatic ovarian cancer screening test to market.”
The progress of OvaDx could present great hope to cancer patients while providing a tremendous upside for investors. The combination of Arrayit and DOCRO could lead to great things for all involved.
Currently, the Arrayit Corporation is trading in the $0.90 range. With the news of this deal and potential throughout the company, Arrayit is a company to keep an eye on.
Let’s hear your thoughts below: